Associate professor Erasmus School of Health Policy & Management Health Technology Assessment (HTA)
- Location
- Burg. Oudlaan 50, Rotterdam
- al@eshpm.eur.nl
More information
‹ Back to overview
Profile
Maiwenn Al obtained her Master degree in Mathematics at Leiden University in 1991. Since 1992 she has been working at the institute for Medical Technology Assessment (iMTA) at Erasmus University Rotterdam. From 1996 to 1999 she held a Pfizer Health Economics Fellowship and in 2001 she obtained her PhD degree at the Erasmus University Rotterdam. Her research focuses on modelling studies and methods for dealing with uncertainty in economic evaluations. Together with Ben van Hout, Maiwenn developed the cost-effectiveness acceptability curve, now widely used as a method to describe uncertainty around ICERs. Her most current research focuses on methods for censored data, including applications in the area of mental health care, and budget allocation models. The latter topic involves both theoretical models and a survey into the decision makers' view on health care objectives and budget constraints.
- Fernando Albuquerque de Almeida, Maiwenn Al, R Koymans, J Riistame, S Pauws & Hans Severens (2020) - Impact of hospitalisation on health-related quality of life in patients with chronic heart failure - Health and Quality of Life Outcomes, 18 (1) - doi: 10.1186/s12955-020-01508-8
- Marscha Holleman, Maiwenn Al, Remziye Zaim, HJM Groen & Carin Groot (2019) - Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations - The European Journal Of Health Economics, 21, 153-164 - doi: 10.1007/s10198-019-01117-3
- RA Vremans, J Geenen, AM Hovels, WG Goettsch, HGM Leufkens & Maiwenn Al (2019) - Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. - Applied Health Economics and Health Policy, 17, 883-893 - doi: 10.1007/s40258-019-00496-1 - [link]
- Marscha Holleman, H van Tinteren, HJM Groen, Maiwenn Al & Carin Groot (2019) - First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis - OncoTargets and Therapy, 12, 1413-1421 - doi: 10.2147/ott.S189438
- E Alemao, S Johal, Maiwenn Al & Maureen Molken (2018) - Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. - Value in Health, 21 (2), 193-202 - doi: 10.1016/j.jval.2017.05.020
- E Alemao, Maiwenn Al, AA Boonen, MD Stevenson, SMM Verstappen, K Michaud, ME Weinblatt & Maureen Molken (2018) - Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. - PLoS One (print), 13 (10) - doi: 10.1371/journal.pone.0205013
- Nasuh Buyukkaramikli, Saskia Groot, R Riemsma, D Fayter, N Armstrong, P Portegijs, S Duffy, J Kleijnen & Maiwenn Al (2018) - Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-018-0708-4
- Margreet Franken, Isaac Corro Ramos, Jeanine Los & Maiwenn Al (2018) - The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios - BMC Family Practice, 19 (31) - doi: 10.1186/s12875-018-0714-9 - [link]
- Isaac Corro Ramos, GAK van Voorn, P (Pepijn) Vemer, TL Feenstra & Maiwenn Al (2017) - A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data - Value in Health, 20 (8), 1041-1047 - doi: 10.1016/j.jval.2017.04.016
- N Büyükkaramikli, Hedwig Blommestein, R Riemsma, N Armstrong, FJ Clay, J Ross, G Worthy, Hans Severens, J Kleijnen & Maiwenn Al (2017) - Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-017-0528-y
- NC Büyükkaramikli, Saskia Groot, D Fayter, R Wolff, N Armstrong, L Stirk, G Worthy, Fernando Albuquerque de Almeida, J Kleijnen & Maiwenn Al (2017) - Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-017-0581-6
- Isaac Corro Ramos, SK Lhachimi, A Gerber-Grote & Maiwenn Al (2016) - Cost Recommendation under Uncertainty in IQWiG’s Efficiency Frontier Framework - Medical Decision Making - doi: 10.1177/0272989X16636856
- R Riemsma, Isaac Corro Ramos, R Birnie, Nasuh Buyukkaramikli, N Armstrong, S Ryder, S Duffy, G Worthy, Maiwenn Al, Hans Severens & J Kleijnen (2016) - Integrated sensor-augmented pump therapy system [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation - Health Technology Assessment, 20 (17) - doi: 10.3310/hta20170
- P (Pepijn) Vemer, Isaac Corro Ramos, GAK van Voorn, Maiwenn Al & TL Feenstra (2016) - AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users - Pharmacoeconomics (Print), 34 (4), 349-361 - doi: 10.1007/s40273-015-0327-2
- J Bindels, B Ramaekers, Isaac Corro Ramos, L Mohseninejad, S Knies, J Grutters, M Postma, Maiwenn Al, TL Feenstra & M Joore (2016) - Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives - Pharmacoeconomics (Print), 34 (3), 315-322 - doi: 10.1007/s40273-015-0346-z
- Hedwig Blommestein, N Armstrong, S Ryder, S Deshpande, G Worthy, C Noake, R Riemsma, J Kleijnen, Hans Severens & Maiwenn Al (2016) - Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene - Pharmacoeconomics (Online), 34 (1), 23-31 - doi: 10.1007/s40273-015-0318-3
- LT (Laura) Burgers, Ken Redekop, Maiwenn Al, SK (Stefan) Lhachimi, N Armstrong, S Walker, C Rothery, M Westwood & Hans Severens (2016) - Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients - European Journal of Health Economics (HEPAC), 1-12 - doi: 10.1007/s10198-016-0824-z
- E Alemao, S Joo, H Kawabata, Maiwenn Al, PD Allison, Maureen Molken, ML Frits, CK Iannaccone, NA Schadik & ME Weinsblatt (2016) - Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data - Arthritis Care & Research, 68 (3), 308-317 - doi: 10.1002/acr.22678
- E Alemao, H Cawston, F Bourhis, Maiwenn Al, Maureen Molken, KP Liao & DH Solomon (2016) - Cardiovascular risk factor management in patients with RA compared to matched non-RA patients - Rheumatology, 55 (5), 809-816 - doi: 10.1093/rheumatology/kev427
- N Armstrong, LT (Laura) Burgers, S Deshpande, Maiwenn Al, R Riemsma, SR Vallabhaneni, P Holt, Hans Severens & J Kleijnen (2015) - The use of fenestrated and branched endovascular aneurysm repairfor juxtarental and thoracoabdominal aneurysms: a systematic review and cost-effectiveness analysis - Health Technology Assessment, 18 (70) - doi: 10.3310/hta18700
- Isaac Corro Ramos, Maureen Molken & Maiwenn Al (2015) - Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis - Value in Health, 18 (1), 100-109 - doi: 10.1016/j.jval.2014.09.003.
- Olena Mandrik, Isaac Corro Ramos, Saskia Knies, Maiwenn Al & Hans Severens (2015) - Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine - Cancer Management and Research (online), 2015 (7), 279-289 - doi: 10.2147/CMAR.S79258
- KM (Kim Marleine) Holtzer - Goor, JG (Jennifer G.) Gaultney, P van Houten, AS Wagg, Simone Huygens, MM Nielen, CP Albers-Heitner, Ken Redekop, Maureen Molken & Maiwenn Al (2015) - Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands. - PLoS One (print), 10 (10) - doi: 10.1371/journal.pone.0138225
- P Whiting, Maiwenn Al, LT (Laura) Burgers, M Westwood, S Ryder, Martine Lips, N Armstrong, A Allen, Hans Severens & J Kleijnen (2014) - Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. - Health Technology Assessment, 18 (8) - doi: 10.3310/hta18180
- Isaac Corro Ramos, Maureen Molken & Maiwenn Al (2013) - The role of value-of-information analysis in a health care research priority setting: a theoretical case study - Medical Decision Making, 33 (4), 472-489 - doi: 10.1177/0272989X12468616
- MRC Hendriks, Maiwenn Al, MHC Bleijlevens, JCM van Haastregt, HFJM Crebolder, JTM van Eijk & SMAA Evers (2013) - Continuous versus intermittent data collection of health care utilization - Medical Decision Making, 33, 998-1008 - doi: 10.1177/0272989X13482045
- P (Pepijn) Vemer, PFM (Paul) Krabbe, TL (Talitha) Feenstra, GAK van Voorn, Isaac Corro Ramos & Maiwenn Al (2013) - Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force - Value in Health, 16, 1106-1107 - doi: 10.1016/j.jval.2013.06.015
- Leona Roijen, TJEM Bakker, Maiwenn Al, J van der Lee, Hugo Duivenvoorden, MW Ribbe & Robbert Huijsman (2013) - Economic evaluation alongside a single RCT of an integrative psychotherapeutic nursing home programme - BMC Health Services Research, 13 (370), 1-13 - doi: 10.1186/1472-6963-13-370
- Martine Lips, Maiwenn Al, KM Beeh, D Bowles, JMG von der Schulenburg, J Lungershausen, BU Monz, H Schmidt, C Vogelmeier & Maureen Molken (2013) - Cost-effectiveness of triotropium versus salmeterol: the POET-COPD trial - European Respiratory Journal, 41 (3), 556-564 - doi: 10.1183/09031936.000.27212
- P (Pepijn) Vemer, Maiwenn Al, M (Mark) Oppe & Maureen Molken (2013) - A Choice That Matters? Simulation study on the impact of direct meta-analysis methods on health economic outcomes - Pharmacoeconomics (Print), 31 (8), 719-730 - doi: 10.1007/s40273-013-0067-0
- Menno Kiel, Esther Röder, Roy Gerth van Wijk, Maiwenn Al, WCJ Hop & Maureen Molken (2013) - Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy - Journal of Allergy and Clinical Immunology, 132, 353-360 - doi: 10.1016/j.jaci.2013.03.013
- Maiwenn Al (2012) - Cost-Effectiveness Acceptability Curves Revisited - Pharmacoeconomics (Print), 31 (2), 93-100 - doi: 10.1007/s40273-012-0011-8
- Martine Lips, Maiwenn Al, KM Beeh, D Bowles, JM Graf von der Schulenburg, J Lungershausen, BU Monz, H Schmidt, C Vogelmeier & Maureen Molken (2012) - Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial - European Respiratory Journal - doi: 10.1183/09031936.00027212
- E Alemao, S Rajagopalan, RE Curiel, J Purvis, SL Yang & Maiwenn Al (2011) - Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma - Journal of Medical Economics, 14 (2), 245-252 - doi: 10.3111/13696998.2011.566296
- EJI Hoogendoorn, Maureen Molken, RT Hoogenveen, Maiwenn Al & TL (Talitha) Feenstra (2011) - Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease - Value in Health, 14 (8), 1039-1047 - doi: 10.1016/j.jval.2011.06.008
- M (Mark) Oppe, Maiwenn Al & Maureen Molken (2011) - Comparing Methods of Data Synthesis - Pharmacoeconomics (Print), 29 (3), 239-250 - doi: 10.2165/11539870-000000000-00000
- Maiwenn Al, Leona Roijen, Siok Swan Tan & Jan Bakker (2010) - Cost-consequence analysis of remifentanil-based analgo-sedation vs. conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands - Critical Care, 14 (195), 1-10 - doi: 10.1186/cc9313
- Lucas Goossens, B Standaert, Nico Hartwig, AM Hovels & Maiwenn Al (2009) - Conclusions on cost-effectiveness of rotavirus vaccination highly dependent on assumptions - Vaccine, 27, 2531-2532 - doi: 10.1016/j.vaccine.2009.02.036
- Leona Roijen, P (Paul) Verboom, R Philips & Maiwenn Al (2009) - The cost utility of solifenacin in the threatment of overactive bladder - International Urology and Nephrology, 41, 293-298 - doi: 10.1007/s11255-008-9448-2
- CM (Carmen) Galani, Maiwenn Al, H Schneider & FFH Rutten (2008) - Uncertainty in decision-making: value of additional information in the cost-effectivenss of lifestyle intervention in overweight and obese people - Value in Health, 11 (3), 424-434 - doi: 10.1111/j.1524-4733.2007.00284.x
- B van den Berg, Maiwenn Al, Job Exel, Marc Koopmanschap & Werner Brouwer (2008) - Economic valuation of informal care: conjoint analysis applied in a heterogeneous population of informal caregivers - Value in Health, 11 (7), 1041-1050 - doi: 10.1111/j.1524-4733.2008.00357.x
- Lucas Goossens, B Standaert, Nico Hartwig, AM Hovels & Maiwenn Al (2008) - The cost-utility of rotavirus vaccination with Rotarix TM (RIX4414) in the Netherlands - Vaccine, 26, 1118-1127 - doi: 10.1016/j.vaccine.2007.11.070
- JB (Jan) Oostenbrink, Maiwenn Al, M (Mark) Oppe & Maureen Molken (2008) - Expected value of perfect information: An Empirical example of reducing decision uncertainty by conducting additional research - Value in Health, 11, 1070-1080 - doi: 10.1111/j.1524-4733.2008.00389.x
- CAM Bouwmans - Frijters, AME Lintsen, Maiwenn Al, CM Verhaak, Rene Eijkemans, Dik Habbema, DDM Braat & Leona Roijen (2008) - Absence from work and emotional stress in woman undergoing IVF or ICSI: An analysis of IVF-related absence from work in women and the contribution of general and emotional factors. - Acta Obstetricia et Gynecologica Scandinavica, 87, 1169-1175 - doi: 10.1080/00016340802460305
- LM (Leida) Lamers, R Stupp, Martin Bent, Maiwenn Al, T Gorlia, JB Wasserfallen, N Mittmann, SJ Seung, R Crott & CAUD Groot (2008) - Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme - A report from the EORTC 26981/22981 NCI-C CE3 intergroup study - Cancer, 112 (6), 1337-1344 - doi: 10.1002/cncr.23297
- Maiwenn Al, N Maniadakis, Els Grijseels & Mirjam Janssen (2008) - Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands - Value in Health, 11 (4), 589-599 - doi: 10.1111/j.1524-4733.2007.00303.x
- JM Lamers, R Stupp, Martin Bent, Maiwenn Al, T Gorlia, JB Wasserfallen, N Mittmann, SJ Seung, R Crott & Carin Groot (2008) - Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme - Cancer, 112 (6), 1337-1344
- Siok Swan Tan, Leona Roijen, Maiwenn Al, CAM Bouwmans - Frijters, ME Hoogendoorn, PE Spronk & Jan Bakker (2008) - A microcosting study of intensive care unit stay in the Netherlands - Journal of Intensive Care Medicine, 23 (4), 250-257 - doi: 10.1177/0885066608318661
- B (Bart) van der Berg, Maiwenn Al, W Brouwer, Job Exel & Marc Koopmanschap (2005) - Economic valuation of informal care: The conjoint measurement method applied to informal caregiving - Social Science & Medicine, 61 (6), 1342-1355 - doi: 10.1016/j.socscimed.2005.01.029
- JB (Jan) Oostenbrink & Maiwenn Al (2005) - The analysis of incomplete cost data due to dropout - Health Economics, 14 (8), 763-776 - doi: 10.1002/hec.966
- Maiwenn Al, TL (Talitha) Feenstra & BA (Ben) van Hout (2005) - Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty - Health Economics, 14 (7), 655-667 - doi: 10.1002/hec.973
- HJ Bernelot Moens, JJ Croonenborg, Maiwenn Al & PM Bemt (2004) - Richtlijn 'NSAID-gebruik en preventie van maagschade' - Nederlands Tijdschrift voor Geneeskunde, 148, 604-608
- P (Pedram) Sendi, Maiwenn Al & FFH Rutten (2004) - Portfolio theory and cost- effectiveness analysis: A further discussion - Value in Health, 7, 595-601 - doi: 10.1111/j.1524-4733.2004.75010.x
- JB (Jan) Oostenbrink, Maureen Molken, Maiwenn Al, JA Noord & W van Vincken (2004) - One-year cost-effectiveness of tiotropium to treat chronic obstructive pulmonary disease - European Respiratory Journal, 23, 241-249 - doi: 10.1183/09031936.03.00083703
- P (Pedram) Sendi, Maiwenn Al, A Gafni & S Birch (2004) - Portfolio theory and the alternative decision rule of cost- effectiveness analysis: theoretical and practical considerations - Social Science & Medicine, 58, 1853-1855 - doi: 10.1016/j.socscimed.2004.01.001
- P (Pedram) Sendi, Maiwenn Al & H Zimmermann (2004) - A risk-adjusted approach to comparing the return on the investment in health care programs - International Journal of Health Care Finance and Economics, 4, 199-210
- Maiwenn Al & Werner Brouwer (2004) - Decision makers views on health care objectives and budget constraints; results from a pilot - Health Policy, 70, 33-48 - doi: 10.1016/j.healthpol.2004.01.009
- P (Pedram) Sendi, Maiwenn Al & M Battegay (2004) - Optimising the performance of an outpatient setting - Swiss Medical Weekly, 134, 44-49
- P (Pedram) Sendi, Maiwenn Al, A Gafni & S Birch (2003) - Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources - Social Science & Medicine, 57, 2207-2215 - doi: 10.1016/S0277-9536(03)00086-8
- P (Pedram) Sendi & Maiwenn Al (2003) - Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty - Social Science & Medicine, 57, 969-974 - doi: 10.1016/S0277-9536(02)00477-X
- JB (Jan) Oostenbrink, Maiwenn Al & Maureen Molken (2003) - Methods to analyse cost data of patients who withdraw in a clinical trial setting - Pharmacoeconomics (Print), 21, 1103-1112 - doi: 10.2165/00019053-200321150-00004
- H (Harry) Suryapranata, JP (Jan Paul) Ottervanger, E Nibbering, AWJ Hof, JCA Hoorntje, Maarten Boer, Maiwenn Al & F Zijlstra (2001) - Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction - Heart, 85 (6), 667-671
- C Chevat, BM Pena, Maiwenn Al & FFH Rutten (2001) - Health care resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective - Pharmacoeconomics (Print), 19 (1), 17-32
- Maiwenn Al & BA (Ben) van Hout (2000) - A bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty - Health Economics, 9, 599-609
- Maiwenn Al, BA (Ben) van Hout, CM Bowine & FFH Rutten (1998) - Sample size calculation in economic evaluations - Health Economics, 7, 327-335
- Maiwenn Al, Marc Koopmanschap, PJ van Enckevort, A Geertsma, W van der Bij, WJ Boer & EM ten Vergert (1998) - Coast- effectiveness of lung transplantation in the Netherlands - Chest, 113 (1), 124-130
- NF de Keizer, Gouke Bonsel, Maiwenn Al & RJBJ Gemke (1998) - The relation between TISS and real paedeatric ICU costs: a case study with generalizable methodology - Intensive Care Medicine, 24, 1062-1069 - doi: 10.1007/s001340050717
- PJ van Enckevort, EM TenVergert, Gouke Bonsel, A Geertsma, W van der Bij, WJ Boer, Marc Koopmanschap, Maiwenn Al & FFH Rutten (1998) - Technology Assessment of the Dutch lung transplantation program - International Journal of Technology Assessment in Health Care, 14 (2), 344-356
- Maiwenn Al, BC (Bowine) Michel & FFH Rutten (1996) - The Cost Effectiveness of Diclofenac Plus Misoprostol Compared with Diclofenac Monotherapy in Patients with Rheumatoid Arthritis - Pharmacoeconomics (Print), 10 (2), 141-151
- BC (Bowine) Michel, Maiwenn Al, WJ Remme, JH Kingma, JA Kragten, R van Nieuwenhuizen & BA (Ben) van Hout (1996) - Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands - European Heart Journal, 17 (May), 731-740
- N Armstrong, Nasuh Buyukkaramikli, Hannah Penton, R Riemsma, Pim Wetzelaer, V Huertas Carrera, SL Swift, T Drachen, H Raatz, S Ryder, D Shah, T Buksnys, G Worthy, S Duffy, Maiwenn Al & J Kleijnen (2020) - Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis - Health Technology Assessment, 51, 1-220 - doi: 10.3310/hta24510.
- Maiwenn Al & Werner Brouwer (2004) - Stimuleren doelmatig gebruik van zuurpompremmers in de onderhoudsbehandeling - TSG, 82, 191-195
- Ivonne Buijt, Maiwenn Al & FFH Rutten (2003) - Protonpompremmers, kostenremmers? - Pharmaceutisch Weekblad, 138, 1194-1199
- Ivonne Buijt, Maiwenn Al & FFH Rutten (2003) - Protonpompremmers, kostenremmers? . - Pharmaceutisch Weekblad, 138, 1428-1429
- JRBJ Brouwers, EN van Roon, M Postma & Maiwenn Al (2000) - Kosteneffectiviteit van NSAID's - Altijd gastoprotectie? - Pharmaceutisch Weekblad, 135 (5), 172-175
- HJ (Herman) Stoevelaar & Maiwenn Al (1995) - Medische statistiek; over getallen die leven en worden geleefd - Klinische Fysica, 1 (1), 25-29
- Maiwenn Al (2000) - Modelleren en omgaan met onzekerheid - Elsevier gezondheidszorg
- Maiwenn Al (2001) - Certain methods for uncertain situations. Evaluating health care technologies - EUR
- Penny Whiting, Maiwenn Al, M Westwood, Isaac Corro Ramos, S Ryder, N Armstrong, K Misso, J Ross, Hans Severens & J Kleijnen (2016) - Viscoelastic point-of-care testing to assist with the diagnosis management and monitoring of haemostasis a systematic review and cost-effectiveness analysis - doi: 10.3310/hta19580 - Health Technology Assessment
- R Riemsma, Maiwenn Al, Isaac Corro Ramos, SN Deshpande, N Armstrong, YC Lee, SD Ryder, C Noake, Marieke Krol, M (Mark) Oppe, J Kleijnen & Hans Severens (2013) - SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis - doi: 10.3310/hta17610 - National Institute for Health Research
- Maiwenn Al (1995) - Hulpambulances nader beschouwd - Begeleidingscommissie experiment hulpambulancevervoer
- M Westwood, Maiwenn Al, LT (Laura) Burgers, Ken Redekop, SK (Stefan) Lhachimi, N Armstrong, H Raatz, K Misso, Hans Severens & J Kleijnen (2013) - A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD. - doi: 10.3310/hta17090 - Health Technology Assessment
- Martine Lips, Maureen Molken, R Hoogeveen, Maiwenn Al & TL (Talitha) Feenstra (2010) - Comparing the cost-effectiveness of a wide range of COPD interventions using a stochastic, dynamic, population model for COPD - Instituut Beleid & Management Gezondheidszorg
- Fernando Albuquerque de Almeida, Maiwenn Al, R Koymans, J Riistame, S Pauws & Hans Severens (2020) - Impact of hospitalisation on health-related quality of life in patients with chronic heart failure - Health and Quality of Life Outcomes, 18 (1) - doi: 10.1186/s12955-020-01508-8
- Marscha Holleman, Maiwenn Al, Remziye Zaim, HJM Groen & Carin Groot (2019) - Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations - The European Journal Of Health Economics, 21, 153-164 - doi: 10.1007/s10198-019-01117-3
- RA Vremans, J Geenen, AM Hovels, WG Goettsch, HGM Leufkens & Maiwenn Al (2019) - Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. - Applied Health Economics and Health Policy, 17, 883-893 - doi: 10.1007/s40258-019-00496-1 - [link]
- Marscha Holleman, H van Tinteren, HJM Groen, Maiwenn Al & Carin Groot (2019) - First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis - OncoTargets and Therapy, 12, 1413-1421 - doi: 10.2147/ott.S189438
- E Alemao, S Johal, Maiwenn Al & Maureen Molken (2018) - Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. - Value in Health, 21 (2), 193-202 - doi: 10.1016/j.jval.2017.05.020
- E Alemao, Maiwenn Al, AA Boonen, MD Stevenson, SMM Verstappen, K Michaud, ME Weinblatt & Maureen Molken (2018) - Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. - PLoS One (print), 13 (10) - doi: 10.1371/journal.pone.0205013
- Nasuh Buyukkaramikli, Saskia Groot, R Riemsma, D Fayter, N Armstrong, P Portegijs, S Duffy, J Kleijnen & Maiwenn Al (2018) - Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-018-0708-4
- Margreet Franken, Isaac Corro Ramos, Jeanine Los & Maiwenn Al (2018) - The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios - BMC Family Practice, 19 (31) - doi: 10.1186/s12875-018-0714-9 - [link]
- Isaac Corro Ramos, GAK van Voorn, P (Pepijn) Vemer, TL Feenstra & Maiwenn Al (2017) - A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data - Value in Health, 20 (8), 1041-1047 - doi: 10.1016/j.jval.2017.04.016
- N Büyükkaramikli, Hedwig Blommestein, R Riemsma, N Armstrong, FJ Clay, J Ross, G Worthy, Hans Severens, J Kleijnen & Maiwenn Al (2017) - Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-017-0528-y
- NC Büyükkaramikli, Saskia Groot, D Fayter, R Wolff, N Armstrong, L Stirk, G Worthy, Fernando Albuquerque de Almeida, J Kleijnen & Maiwenn Al (2017) - Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-017-0581-6
- Isaac Corro Ramos, SK Lhachimi, A Gerber-Grote & Maiwenn Al (2016) - Cost Recommendation under Uncertainty in IQWiG’s Efficiency Frontier Framework - Medical Decision Making - doi: 10.1177/0272989X16636856
- R Riemsma, Isaac Corro Ramos, R Birnie, Nasuh Buyukkaramikli, N Armstrong, S Ryder, S Duffy, G Worthy, Maiwenn Al, Hans Severens & J Kleijnen (2016) - Integrated sensor-augmented pump therapy system [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation - Health Technology Assessment, 20 (17) - doi: 10.3310/hta20170
- P (Pepijn) Vemer, Isaac Corro Ramos, GAK van Voorn, Maiwenn Al & TL Feenstra (2016) - AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users - Pharmacoeconomics (Print), 34 (4), 349-361 - doi: 10.1007/s40273-015-0327-2
- J Bindels, B Ramaekers, Isaac Corro Ramos, L Mohseninejad, S Knies, J Grutters, M Postma, Maiwenn Al, TL Feenstra & M Joore (2016) - Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives - Pharmacoeconomics (Print), 34 (3), 315-322 - doi: 10.1007/s40273-015-0346-z
- Hedwig Blommestein, N Armstrong, S Ryder, S Deshpande, G Worthy, C Noake, R Riemsma, J Kleijnen, Hans Severens & Maiwenn Al (2016) - Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene - Pharmacoeconomics (Online), 34 (1), 23-31 - doi: 10.1007/s40273-015-0318-3
- LT (Laura) Burgers, Ken Redekop, Maiwenn Al, SK (Stefan) Lhachimi, N Armstrong, S Walker, C Rothery, M Westwood & Hans Severens (2016) - Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients - European Journal of Health Economics (HEPAC), 1-12 - doi: 10.1007/s10198-016-0824-z
- E Alemao, S Joo, H Kawabata, Maiwenn Al, PD Allison, Maureen Molken, ML Frits, CK Iannaccone, NA Schadik & ME Weinsblatt (2016) - Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data - Arthritis Care & Research, 68 (3), 308-317 - doi: 10.1002/acr.22678
- E Alemao, H Cawston, F Bourhis, Maiwenn Al, Maureen Molken, KP Liao & DH Solomon (2016) - Cardiovascular risk factor management in patients with RA compared to matched non-RA patients - Rheumatology, 55 (5), 809-816 - doi: 10.1093/rheumatology/kev427
- N Armstrong, LT (Laura) Burgers, S Deshpande, Maiwenn Al, R Riemsma, SR Vallabhaneni, P Holt, Hans Severens & J Kleijnen (2015) - The use of fenestrated and branched endovascular aneurysm repairfor juxtarental and thoracoabdominal aneurysms: a systematic review and cost-effectiveness analysis - Health Technology Assessment, 18 (70) - doi: 10.3310/hta18700
- Isaac Corro Ramos, Maureen Molken & Maiwenn Al (2015) - Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis - Value in Health, 18 (1), 100-109 - doi: 10.1016/j.jval.2014.09.003.
- Olena Mandrik, Isaac Corro Ramos, Saskia Knies, Maiwenn Al & Hans Severens (2015) - Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine - Cancer Management and Research (online), 2015 (7), 279-289 - doi: 10.2147/CMAR.S79258
- KM (Kim Marleine) Holtzer - Goor, JG (Jennifer G.) Gaultney, P van Houten, AS Wagg, Simone Huygens, MM Nielen, CP Albers-Heitner, Ken Redekop, Maureen Molken & Maiwenn Al (2015) - Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands. - PLoS One (print), 10 (10) - doi: 10.1371/journal.pone.0138225
- P Whiting, Maiwenn Al, LT (Laura) Burgers, M Westwood, S Ryder, Martine Lips, N Armstrong, A Allen, Hans Severens & J Kleijnen (2014) - Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. - Health Technology Assessment, 18 (8) - doi: 10.3310/hta18180
- Isaac Corro Ramos, Maureen Molken & Maiwenn Al (2013) - The role of value-of-information analysis in a health care research priority setting: a theoretical case study - Medical Decision Making, 33 (4), 472-489 - doi: 10.1177/0272989X12468616
- MRC Hendriks, Maiwenn Al, MHC Bleijlevens, JCM van Haastregt, HFJM Crebolder, JTM van Eijk & SMAA Evers (2013) - Continuous versus intermittent data collection of health care utilization - Medical Decision Making, 33, 998-1008 - doi: 10.1177/0272989X13482045
- P (Pepijn) Vemer, PFM (Paul) Krabbe, TL (Talitha) Feenstra, GAK van Voorn, Isaac Corro Ramos & Maiwenn Al (2013) - Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force - Value in Health, 16, 1106-1107 - doi: 10.1016/j.jval.2013.06.015
- Leona Roijen, TJEM Bakker, Maiwenn Al, J van der Lee, Hugo Duivenvoorden, MW Ribbe & Robbert Huijsman (2013) - Economic evaluation alongside a single RCT of an integrative psychotherapeutic nursing home programme - BMC Health Services Research, 13 (370), 1-13 - doi: 10.1186/1472-6963-13-370
- Martine Lips, Maiwenn Al, KM Beeh, D Bowles, JMG von der Schulenburg, J Lungershausen, BU Monz, H Schmidt, C Vogelmeier & Maureen Molken (2013) - Cost-effectiveness of triotropium versus salmeterol: the POET-COPD trial - European Respiratory Journal, 41 (3), 556-564 - doi: 10.1183/09031936.000.27212
- P (Pepijn) Vemer, Maiwenn Al, M (Mark) Oppe & Maureen Molken (2013) - A Choice That Matters? Simulation study on the impact of direct meta-analysis methods on health economic outcomes - Pharmacoeconomics (Print), 31 (8), 719-730 - doi: 10.1007/s40273-013-0067-0
- Menno Kiel, Esther Röder, Roy Gerth van Wijk, Maiwenn Al, WCJ Hop & Maureen Molken (2013) - Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy - Journal of Allergy and Clinical Immunology, 132, 353-360 - doi: 10.1016/j.jaci.2013.03.013
- Maiwenn Al (2012) - Cost-Effectiveness Acceptability Curves Revisited - Pharmacoeconomics (Print), 31 (2), 93-100 - doi: 10.1007/s40273-012-0011-8
- Martine Lips, Maiwenn Al, KM Beeh, D Bowles, JM Graf von der Schulenburg, J Lungershausen, BU Monz, H Schmidt, C Vogelmeier & Maureen Molken (2012) - Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial - European Respiratory Journal - doi: 10.1183/09031936.00027212
- E Alemao, S Rajagopalan, RE Curiel, J Purvis, SL Yang & Maiwenn Al (2011) - Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma - Journal of Medical Economics, 14 (2), 245-252 - doi: 10.3111/13696998.2011.566296
- EJI Hoogendoorn, Maureen Molken, RT Hoogenveen, Maiwenn Al & TL (Talitha) Feenstra (2011) - Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease - Value in Health, 14 (8), 1039-1047 - doi: 10.1016/j.jval.2011.06.008
- M (Mark) Oppe, Maiwenn Al & Maureen Molken (2011) - Comparing Methods of Data Synthesis - Pharmacoeconomics (Print), 29 (3), 239-250 - doi: 10.2165/11539870-000000000-00000
- Maiwenn Al, Leona Roijen, Siok Swan Tan & Jan Bakker (2010) - Cost-consequence analysis of remifentanil-based analgo-sedation vs. conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands - Critical Care, 14 (195), 1-10 - doi: 10.1186/cc9313
- Lucas Goossens, B Standaert, Nico Hartwig, AM Hovels & Maiwenn Al (2009) - Conclusions on cost-effectiveness of rotavirus vaccination highly dependent on assumptions - Vaccine, 27, 2531-2532 - doi: 10.1016/j.vaccine.2009.02.036
- Leona Roijen, P (Paul) Verboom, R Philips & Maiwenn Al (2009) - The cost utility of solifenacin in the threatment of overactive bladder - International Urology and Nephrology, 41, 293-298 - doi: 10.1007/s11255-008-9448-2
- CM (Carmen) Galani, Maiwenn Al, H Schneider & FFH Rutten (2008) - Uncertainty in decision-making: value of additional information in the cost-effectivenss of lifestyle intervention in overweight and obese people - Value in Health, 11 (3), 424-434 - doi: 10.1111/j.1524-4733.2007.00284.x
- B van den Berg, Maiwenn Al, Job Exel, Marc Koopmanschap & Werner Brouwer (2008) - Economic valuation of informal care: conjoint analysis applied in a heterogeneous population of informal caregivers - Value in Health, 11 (7), 1041-1050 - doi: 10.1111/j.1524-4733.2008.00357.x
- Lucas Goossens, B Standaert, Nico Hartwig, AM Hovels & Maiwenn Al (2008) - The cost-utility of rotavirus vaccination with Rotarix TM (RIX4414) in the Netherlands - Vaccine, 26, 1118-1127 - doi: 10.1016/j.vaccine.2007.11.070
- JB (Jan) Oostenbrink, Maiwenn Al, M (Mark) Oppe & Maureen Molken (2008) - Expected value of perfect information: An Empirical example of reducing decision uncertainty by conducting additional research - Value in Health, 11, 1070-1080 - doi: 10.1111/j.1524-4733.2008.00389.x
- CAM Bouwmans - Frijters, AME Lintsen, Maiwenn Al, CM Verhaak, Rene Eijkemans, Dik Habbema, DDM Braat & Leona Roijen (2008) - Absence from work and emotional stress in woman undergoing IVF or ICSI: An analysis of IVF-related absence from work in women and the contribution of general and emotional factors. - Acta Obstetricia et Gynecologica Scandinavica, 87, 1169-1175 - doi: 10.1080/00016340802460305
- LM (Leida) Lamers, R Stupp, Martin Bent, Maiwenn Al, T Gorlia, JB Wasserfallen, N Mittmann, SJ Seung, R Crott & CAUD Groot (2008) - Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme - A report from the EORTC 26981/22981 NCI-C CE3 intergroup study - Cancer, 112 (6), 1337-1344 - doi: 10.1002/cncr.23297
- Maiwenn Al, N Maniadakis, Els Grijseels & Mirjam Janssen (2008) - Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands - Value in Health, 11 (4), 589-599 - doi: 10.1111/j.1524-4733.2007.00303.x
- JM Lamers, R Stupp, Martin Bent, Maiwenn Al, T Gorlia, JB Wasserfallen, N Mittmann, SJ Seung, R Crott & Carin Groot (2008) - Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme - Cancer, 112 (6), 1337-1344
- Siok Swan Tan, Leona Roijen, Maiwenn Al, CAM Bouwmans - Frijters, ME Hoogendoorn, PE Spronk & Jan Bakker (2008) - A microcosting study of intensive care unit stay in the Netherlands - Journal of Intensive Care Medicine, 23 (4), 250-257 - doi: 10.1177/0885066608318661
- B (Bart) van der Berg, Maiwenn Al, W Brouwer, Job Exel & Marc Koopmanschap (2005) - Economic valuation of informal care: The conjoint measurement method applied to informal caregiving - Social Science & Medicine, 61 (6), 1342-1355 - doi: 10.1016/j.socscimed.2005.01.029
- JB (Jan) Oostenbrink & Maiwenn Al (2005) - The analysis of incomplete cost data due to dropout - Health Economics, 14 (8), 763-776 - doi: 10.1002/hec.966
- Maiwenn Al, TL (Talitha) Feenstra & BA (Ben) van Hout (2005) - Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty - Health Economics, 14 (7), 655-667 - doi: 10.1002/hec.973
- HJ Bernelot Moens, JJ Croonenborg, Maiwenn Al & PM Bemt (2004) - Richtlijn 'NSAID-gebruik en preventie van maagschade' - Nederlands Tijdschrift voor Geneeskunde, 148, 604-608
- P (Pedram) Sendi, Maiwenn Al & FFH Rutten (2004) - Portfolio theory and cost- effectiveness analysis: A further discussion - Value in Health, 7, 595-601 - doi: 10.1111/j.1524-4733.2004.75010.x
- JB (Jan) Oostenbrink, Maureen Molken, Maiwenn Al, JA Noord & W van Vincken (2004) - One-year cost-effectiveness of tiotropium to treat chronic obstructive pulmonary disease - European Respiratory Journal, 23, 241-249 - doi: 10.1183/09031936.03.00083703
- P (Pedram) Sendi, Maiwenn Al, A Gafni & S Birch (2004) - Portfolio theory and the alternative decision rule of cost- effectiveness analysis: theoretical and practical considerations - Social Science & Medicine, 58, 1853-1855 - doi: 10.1016/j.socscimed.2004.01.001
- P (Pedram) Sendi, Maiwenn Al & H Zimmermann (2004) - A risk-adjusted approach to comparing the return on the investment in health care programs - International Journal of Health Care Finance and Economics, 4, 199-210
- Maiwenn Al & Werner Brouwer (2004) - Decision makers views on health care objectives and budget constraints; results from a pilot - Health Policy, 70, 33-48 - doi: 10.1016/j.healthpol.2004.01.009
- P (Pedram) Sendi, Maiwenn Al & M Battegay (2004) - Optimising the performance of an outpatient setting - Swiss Medical Weekly, 134, 44-49
- P (Pedram) Sendi, Maiwenn Al, A Gafni & S Birch (2003) - Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources - Social Science & Medicine, 57, 2207-2215 - doi: 10.1016/S0277-9536(03)00086-8
- P (Pedram) Sendi & Maiwenn Al (2003) - Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty - Social Science & Medicine, 57, 969-974 - doi: 10.1016/S0277-9536(02)00477-X
- JB (Jan) Oostenbrink, Maiwenn Al & Maureen Molken (2003) - Methods to analyse cost data of patients who withdraw in a clinical trial setting - Pharmacoeconomics (Print), 21, 1103-1112 - doi: 10.2165/00019053-200321150-00004
- H (Harry) Suryapranata, JP (Jan Paul) Ottervanger, E Nibbering, AWJ Hof, JCA Hoorntje, Maarten Boer, Maiwenn Al & F Zijlstra (2001) - Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction - Heart, 85 (6), 667-671
- C Chevat, BM Pena, Maiwenn Al & FFH Rutten (2001) - Health care resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective - Pharmacoeconomics (Print), 19 (1), 17-32
- Maiwenn Al & BA (Ben) van Hout (2000) - A bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty - Health Economics, 9, 599-609
- Maiwenn Al, BA (Ben) van Hout, CM Bowine & FFH Rutten (1998) - Sample size calculation in economic evaluations - Health Economics, 7, 327-335
- Maiwenn Al, Marc Koopmanschap, PJ van Enckevort, A Geertsma, W van der Bij, WJ Boer & EM ten Vergert (1998) - Coast- effectiveness of lung transplantation in the Netherlands - Chest, 113 (1), 124-130
- NF de Keizer, Gouke Bonsel, Maiwenn Al & RJBJ Gemke (1998) - The relation between TISS and real paedeatric ICU costs: a case study with generalizable methodology - Intensive Care Medicine, 24, 1062-1069 - doi: 10.1007/s001340050717
- PJ van Enckevort, EM TenVergert, Gouke Bonsel, A Geertsma, W van der Bij, WJ Boer, Marc Koopmanschap, Maiwenn Al & FFH Rutten (1998) - Technology Assessment of the Dutch lung transplantation program - International Journal of Technology Assessment in Health Care, 14 (2), 344-356
- Maiwenn Al, BC (Bowine) Michel & FFH Rutten (1996) - The Cost Effectiveness of Diclofenac Plus Misoprostol Compared with Diclofenac Monotherapy in Patients with Rheumatoid Arthritis - Pharmacoeconomics (Print), 10 (2), 141-151
- BC (Bowine) Michel, Maiwenn Al, WJ Remme, JH Kingma, JA Kragten, R van Nieuwenhuizen & BA (Ben) van Hout (1996) - Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands - European Heart Journal, 17 (May), 731-740
- N Armstrong, Nasuh Buyukkaramikli, Hannah Penton, R Riemsma, Pim Wetzelaer, V Huertas Carrera, SL Swift, T Drachen, H Raatz, S Ryder, D Shah, T Buksnys, G Worthy, S Duffy, Maiwenn Al & J Kleijnen (2020) - Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis - Health Technology Assessment, 51, 1-220 - doi: 10.3310/hta24510.
- Maiwenn Al & Werner Brouwer (2004) - Stimuleren doelmatig gebruik van zuurpompremmers in de onderhoudsbehandeling - TSG, 82, 191-195
- Ivonne Buijt, Maiwenn Al & FFH Rutten (2003) - Protonpompremmers, kostenremmers? - Pharmaceutisch Weekblad, 138, 1194-1199
- Ivonne Buijt, Maiwenn Al & FFH Rutten (2003) - Protonpompremmers, kostenremmers? . - Pharmaceutisch Weekblad, 138, 1428-1429
- JRBJ Brouwers, EN van Roon, M Postma & Maiwenn Al (2000) - Kosteneffectiviteit van NSAID's - Altijd gastoprotectie? - Pharmaceutisch Weekblad, 135 (5), 172-175
- HJ (Herman) Stoevelaar & Maiwenn Al (1995) - Medische statistiek; over getallen die leven en worden geleefd - Klinische Fysica, 1 (1), 25-29
- Fernando Albuquerque de Almeida, Maiwenn Al, R Koymans, J Riistame, S Pauws & Hans Severens (2020) - Impact of hospitalisation on health-related quality of life in patients with chronic heart failure - Health and Quality of Life Outcomes, 18 (1) - doi: 10.1186/s12955-020-01508-8
- Marscha Holleman, Maiwenn Al, Remziye Zaim, HJM Groen & Carin Groot (2019) - Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations - The European Journal Of Health Economics, 21, 153-164 - doi: 10.1007/s10198-019-01117-3
- RA Vremans, J Geenen, AM Hovels, WG Goettsch, HGM Leufkens & Maiwenn Al (2019) - Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. - Applied Health Economics and Health Policy, 17, 883-893 - doi: 10.1007/s40258-019-00496-1 - [link]
- Marscha Holleman, H van Tinteren, HJM Groen, Maiwenn Al & Carin Groot (2019) - First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis - OncoTargets and Therapy, 12, 1413-1421 - doi: 10.2147/ott.S189438
- E Alemao, S Johal, Maiwenn Al & Maureen Molken (2018) - Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. - Value in Health, 21 (2), 193-202 - doi: 10.1016/j.jval.2017.05.020
- E Alemao, Maiwenn Al, AA Boonen, MD Stevenson, SMM Verstappen, K Michaud, ME Weinblatt & Maureen Molken (2018) - Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. - PLoS One (print), 13 (10) - doi: 10.1371/journal.pone.0205013
- Nasuh Buyukkaramikli, Saskia Groot, R Riemsma, D Fayter, N Armstrong, P Portegijs, S Duffy, J Kleijnen & Maiwenn Al (2018) - Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-018-0708-4
- Margreet Franken, Isaac Corro Ramos, Jeanine Los & Maiwenn Al (2018) - The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios - BMC Family Practice, 19 (31) - doi: 10.1186/s12875-018-0714-9 - [link]
- Isaac Corro Ramos, GAK van Voorn, P (Pepijn) Vemer, TL Feenstra & Maiwenn Al (2017) - A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data - Value in Health, 20 (8), 1041-1047 - doi: 10.1016/j.jval.2017.04.016
- N Büyükkaramikli, Hedwig Blommestein, R Riemsma, N Armstrong, FJ Clay, J Ross, G Worthy, Hans Severens, J Kleijnen & Maiwenn Al (2017) - Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-017-0528-y
- NC Büyükkaramikli, Saskia Groot, D Fayter, R Wolff, N Armstrong, L Stirk, G Worthy, Fernando Albuquerque de Almeida, J Kleijnen & Maiwenn Al (2017) - Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-017-0581-6
- Isaac Corro Ramos, SK Lhachimi, A Gerber-Grote & Maiwenn Al (2016) - Cost Recommendation under Uncertainty in IQWiG’s Efficiency Frontier Framework - Medical Decision Making - doi: 10.1177/0272989X16636856
- R Riemsma, Isaac Corro Ramos, R Birnie, Nasuh Buyukkaramikli, N Armstrong, S Ryder, S Duffy, G Worthy, Maiwenn Al, Hans Severens & J Kleijnen (2016) - Integrated sensor-augmented pump therapy system [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation - Health Technology Assessment, 20 (17) - doi: 10.3310/hta20170
- P (Pepijn) Vemer, Isaac Corro Ramos, GAK van Voorn, Maiwenn Al & TL Feenstra (2016) - AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users - Pharmacoeconomics (Print), 34 (4), 349-361 - doi: 10.1007/s40273-015-0327-2
- J Bindels, B Ramaekers, Isaac Corro Ramos, L Mohseninejad, S Knies, J Grutters, M Postma, Maiwenn Al, TL Feenstra & M Joore (2016) - Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives - Pharmacoeconomics (Print), 34 (3), 315-322 - doi: 10.1007/s40273-015-0346-z
- Hedwig Blommestein, N Armstrong, S Ryder, S Deshpande, G Worthy, C Noake, R Riemsma, J Kleijnen, Hans Severens & Maiwenn Al (2016) - Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene - Pharmacoeconomics (Online), 34 (1), 23-31 - doi: 10.1007/s40273-015-0318-3
- LT (Laura) Burgers, Ken Redekop, Maiwenn Al, SK (Stefan) Lhachimi, N Armstrong, S Walker, C Rothery, M Westwood & Hans Severens (2016) - Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients - European Journal of Health Economics (HEPAC), 1-12 - doi: 10.1007/s10198-016-0824-z
- E Alemao, S Joo, H Kawabata, Maiwenn Al, PD Allison, Maureen Molken, ML Frits, CK Iannaccone, NA Schadik & ME Weinsblatt (2016) - Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data - Arthritis Care & Research, 68 (3), 308-317 - doi: 10.1002/acr.22678
- E Alemao, H Cawston, F Bourhis, Maiwenn Al, Maureen Molken, KP Liao & DH Solomon (2016) - Cardiovascular risk factor management in patients with RA compared to matched non-RA patients - Rheumatology, 55 (5), 809-816 - doi: 10.1093/rheumatology/kev427
- N Armstrong, LT (Laura) Burgers, S Deshpande, Maiwenn Al, R Riemsma, SR Vallabhaneni, P Holt, Hans Severens & J Kleijnen (2015) - The use of fenestrated and branched endovascular aneurysm repairfor juxtarental and thoracoabdominal aneurysms: a systematic review and cost-effectiveness analysis - Health Technology Assessment, 18 (70) - doi: 10.3310/hta18700
- Isaac Corro Ramos, Maureen Molken & Maiwenn Al (2015) - Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis - Value in Health, 18 (1), 100-109 - doi: 10.1016/j.jval.2014.09.003.
- Olena Mandrik, Isaac Corro Ramos, Saskia Knies, Maiwenn Al & Hans Severens (2015) - Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine - Cancer Management and Research (online), 2015 (7), 279-289 - doi: 10.2147/CMAR.S79258
- KM (Kim Marleine) Holtzer - Goor, JG (Jennifer G.) Gaultney, P van Houten, AS Wagg, Simone Huygens, MM Nielen, CP Albers-Heitner, Ken Redekop, Maureen Molken & Maiwenn Al (2015) - Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands. - PLoS One (print), 10 (10) - doi: 10.1371/journal.pone.0138225
- P Whiting, Maiwenn Al, LT (Laura) Burgers, M Westwood, S Ryder, Martine Lips, N Armstrong, A Allen, Hans Severens & J Kleijnen (2014) - Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. - Health Technology Assessment, 18 (8) - doi: 10.3310/hta18180
- Isaac Corro Ramos, Maureen Molken & Maiwenn Al (2013) - The role of value-of-information analysis in a health care research priority setting: a theoretical case study - Medical Decision Making, 33 (4), 472-489 - doi: 10.1177/0272989X12468616
- MRC Hendriks, Maiwenn Al, MHC Bleijlevens, JCM van Haastregt, HFJM Crebolder, JTM van Eijk & SMAA Evers (2013) - Continuous versus intermittent data collection of health care utilization - Medical Decision Making, 33, 998-1008 - doi: 10.1177/0272989X13482045
- P (Pepijn) Vemer, PFM (Paul) Krabbe, TL (Talitha) Feenstra, GAK van Voorn, Isaac Corro Ramos & Maiwenn Al (2013) - Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force - Value in Health, 16, 1106-1107 - doi: 10.1016/j.jval.2013.06.015
- Leona Roijen, TJEM Bakker, Maiwenn Al, J van der Lee, Hugo Duivenvoorden, MW Ribbe & Robbert Huijsman (2013) - Economic evaluation alongside a single RCT of an integrative psychotherapeutic nursing home programme - BMC Health Services Research, 13 (370), 1-13 - doi: 10.1186/1472-6963-13-370
- Martine Lips, Maiwenn Al, KM Beeh, D Bowles, JMG von der Schulenburg, J Lungershausen, BU Monz, H Schmidt, C Vogelmeier & Maureen Molken (2013) - Cost-effectiveness of triotropium versus salmeterol: the POET-COPD trial - European Respiratory Journal, 41 (3), 556-564 - doi: 10.1183/09031936.000.27212
- P (Pepijn) Vemer, Maiwenn Al, M (Mark) Oppe & Maureen Molken (2013) - A Choice That Matters? Simulation study on the impact of direct meta-analysis methods on health economic outcomes - Pharmacoeconomics (Print), 31 (8), 719-730 - doi: 10.1007/s40273-013-0067-0
- Menno Kiel, Esther Röder, Roy Gerth van Wijk, Maiwenn Al, WCJ Hop & Maureen Molken (2013) - Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy - Journal of Allergy and Clinical Immunology, 132, 353-360 - doi: 10.1016/j.jaci.2013.03.013
- Maiwenn Al (2012) - Cost-Effectiveness Acceptability Curves Revisited - Pharmacoeconomics (Print), 31 (2), 93-100 - doi: 10.1007/s40273-012-0011-8
- Martine Lips, Maiwenn Al, KM Beeh, D Bowles, JM Graf von der Schulenburg, J Lungershausen, BU Monz, H Schmidt, C Vogelmeier & Maureen Molken (2012) - Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial - European Respiratory Journal - doi: 10.1183/09031936.00027212
- E Alemao, S Rajagopalan, RE Curiel, J Purvis, SL Yang & Maiwenn Al (2011) - Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma - Journal of Medical Economics, 14 (2), 245-252 - doi: 10.3111/13696998.2011.566296
- EJI Hoogendoorn, Maureen Molken, RT Hoogenveen, Maiwenn Al & TL (Talitha) Feenstra (2011) - Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease - Value in Health, 14 (8), 1039-1047 - doi: 10.1016/j.jval.2011.06.008
- M (Mark) Oppe, Maiwenn Al & Maureen Molken (2011) - Comparing Methods of Data Synthesis - Pharmacoeconomics (Print), 29 (3), 239-250 - doi: 10.2165/11539870-000000000-00000
- Maiwenn Al, Leona Roijen, Siok Swan Tan & Jan Bakker (2010) - Cost-consequence analysis of remifentanil-based analgo-sedation vs. conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands - Critical Care, 14 (195), 1-10 - doi: 10.1186/cc9313
- Lucas Goossens, B Standaert, Nico Hartwig, AM Hovels & Maiwenn Al (2009) - Conclusions on cost-effectiveness of rotavirus vaccination highly dependent on assumptions - Vaccine, 27, 2531-2532 - doi: 10.1016/j.vaccine.2009.02.036
- Leona Roijen, P (Paul) Verboom, R Philips & Maiwenn Al (2009) - The cost utility of solifenacin in the threatment of overactive bladder - International Urology and Nephrology, 41, 293-298 - doi: 10.1007/s11255-008-9448-2
- CM (Carmen) Galani, Maiwenn Al, H Schneider & FFH Rutten (2008) - Uncertainty in decision-making: value of additional information in the cost-effectivenss of lifestyle intervention in overweight and obese people - Value in Health, 11 (3), 424-434 - doi: 10.1111/j.1524-4733.2007.00284.x
- B van den Berg, Maiwenn Al, Job Exel, Marc Koopmanschap & Werner Brouwer (2008) - Economic valuation of informal care: conjoint analysis applied in a heterogeneous population of informal caregivers - Value in Health, 11 (7), 1041-1050 - doi: 10.1111/j.1524-4733.2008.00357.x
- Lucas Goossens, B Standaert, Nico Hartwig, AM Hovels & Maiwenn Al (2008) - The cost-utility of rotavirus vaccination with Rotarix TM (RIX4414) in the Netherlands - Vaccine, 26, 1118-1127 - doi: 10.1016/j.vaccine.2007.11.070
- JB (Jan) Oostenbrink, Maiwenn Al, M (Mark) Oppe & Maureen Molken (2008) - Expected value of perfect information: An Empirical example of reducing decision uncertainty by conducting additional research - Value in Health, 11, 1070-1080 - doi: 10.1111/j.1524-4733.2008.00389.x
- CAM Bouwmans - Frijters, AME Lintsen, Maiwenn Al, CM Verhaak, Rene Eijkemans, Dik Habbema, DDM Braat & Leona Roijen (2008) - Absence from work and emotional stress in woman undergoing IVF or ICSI: An analysis of IVF-related absence from work in women and the contribution of general and emotional factors. - Acta Obstetricia et Gynecologica Scandinavica, 87, 1169-1175 - doi: 10.1080/00016340802460305
- LM (Leida) Lamers, R Stupp, Martin Bent, Maiwenn Al, T Gorlia, JB Wasserfallen, N Mittmann, SJ Seung, R Crott & CAUD Groot (2008) - Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme - A report from the EORTC 26981/22981 NCI-C CE3 intergroup study - Cancer, 112 (6), 1337-1344 - doi: 10.1002/cncr.23297
- Maiwenn Al, N Maniadakis, Els Grijseels & Mirjam Janssen (2008) - Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands - Value in Health, 11 (4), 589-599 - doi: 10.1111/j.1524-4733.2007.00303.x
- JM Lamers, R Stupp, Martin Bent, Maiwenn Al, T Gorlia, JB Wasserfallen, N Mittmann, SJ Seung, R Crott & Carin Groot (2008) - Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme - Cancer, 112 (6), 1337-1344
- Siok Swan Tan, Leona Roijen, Maiwenn Al, CAM Bouwmans - Frijters, ME Hoogendoorn, PE Spronk & Jan Bakker (2008) - A microcosting study of intensive care unit stay in the Netherlands - Journal of Intensive Care Medicine, 23 (4), 250-257 - doi: 10.1177/0885066608318661
- B (Bart) van der Berg, Maiwenn Al, W Brouwer, Job Exel & Marc Koopmanschap (2005) - Economic valuation of informal care: The conjoint measurement method applied to informal caregiving - Social Science & Medicine, 61 (6), 1342-1355 - doi: 10.1016/j.socscimed.2005.01.029
- JB (Jan) Oostenbrink & Maiwenn Al (2005) - The analysis of incomplete cost data due to dropout - Health Economics, 14 (8), 763-776 - doi: 10.1002/hec.966
- Maiwenn Al, TL (Talitha) Feenstra & BA (Ben) van Hout (2005) - Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty - Health Economics, 14 (7), 655-667 - doi: 10.1002/hec.973
- HJ Bernelot Moens, JJ Croonenborg, Maiwenn Al & PM Bemt (2004) - Richtlijn 'NSAID-gebruik en preventie van maagschade' - Nederlands Tijdschrift voor Geneeskunde, 148, 604-608
- P (Pedram) Sendi, Maiwenn Al & FFH Rutten (2004) - Portfolio theory and cost- effectiveness analysis: A further discussion - Value in Health, 7, 595-601 - doi: 10.1111/j.1524-4733.2004.75010.x
- JB (Jan) Oostenbrink, Maureen Molken, Maiwenn Al, JA Noord & W van Vincken (2004) - One-year cost-effectiveness of tiotropium to treat chronic obstructive pulmonary disease - European Respiratory Journal, 23, 241-249 - doi: 10.1183/09031936.03.00083703
- P (Pedram) Sendi, Maiwenn Al, A Gafni & S Birch (2004) - Portfolio theory and the alternative decision rule of cost- effectiveness analysis: theoretical and practical considerations - Social Science & Medicine, 58, 1853-1855 - doi: 10.1016/j.socscimed.2004.01.001
- P (Pedram) Sendi, Maiwenn Al & H Zimmermann (2004) - A risk-adjusted approach to comparing the return on the investment in health care programs - International Journal of Health Care Finance and Economics, 4, 199-210
- Maiwenn Al & Werner Brouwer (2004) - Decision makers views on health care objectives and budget constraints; results from a pilot - Health Policy, 70, 33-48 - doi: 10.1016/j.healthpol.2004.01.009
- P (Pedram) Sendi, Maiwenn Al & M Battegay (2004) - Optimising the performance of an outpatient setting - Swiss Medical Weekly, 134, 44-49
- P (Pedram) Sendi, Maiwenn Al, A Gafni & S Birch (2003) - Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources - Social Science & Medicine, 57, 2207-2215 - doi: 10.1016/S0277-9536(03)00086-8
- P (Pedram) Sendi & Maiwenn Al (2003) - Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty - Social Science & Medicine, 57, 969-974 - doi: 10.1016/S0277-9536(02)00477-X
- JB (Jan) Oostenbrink, Maiwenn Al & Maureen Molken (2003) - Methods to analyse cost data of patients who withdraw in a clinical trial setting - Pharmacoeconomics (Print), 21, 1103-1112 - doi: 10.2165/00019053-200321150-00004
- H (Harry) Suryapranata, JP (Jan Paul) Ottervanger, E Nibbering, AWJ Hof, JCA Hoorntje, Maarten Boer, Maiwenn Al & F Zijlstra (2001) - Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction - Heart, 85 (6), 667-671
- C Chevat, BM Pena, Maiwenn Al & FFH Rutten (2001) - Health care resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective - Pharmacoeconomics (Print), 19 (1), 17-32
- Maiwenn Al & BA (Ben) van Hout (2000) - A bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty - Health Economics, 9, 599-609
- Maiwenn Al, BA (Ben) van Hout, CM Bowine & FFH Rutten (1998) - Sample size calculation in economic evaluations - Health Economics, 7, 327-335
- Maiwenn Al, Marc Koopmanschap, PJ van Enckevort, A Geertsma, W van der Bij, WJ Boer & EM ten Vergert (1998) - Coast- effectiveness of lung transplantation in the Netherlands - Chest, 113 (1), 124-130
- NF de Keizer, Gouke Bonsel, Maiwenn Al & RJBJ Gemke (1998) - The relation between TISS and real paedeatric ICU costs: a case study with generalizable methodology - Intensive Care Medicine, 24, 1062-1069 - doi: 10.1007/s001340050717
- PJ van Enckevort, EM TenVergert, Gouke Bonsel, A Geertsma, W van der Bij, WJ Boer, Marc Koopmanschap, Maiwenn Al & FFH Rutten (1998) - Technology Assessment of the Dutch lung transplantation program - International Journal of Technology Assessment in Health Care, 14 (2), 344-356
- Maiwenn Al, BC (Bowine) Michel & FFH Rutten (1996) - The Cost Effectiveness of Diclofenac Plus Misoprostol Compared with Diclofenac Monotherapy in Patients with Rheumatoid Arthritis - Pharmacoeconomics (Print), 10 (2), 141-151
- BC (Bowine) Michel, Maiwenn Al, WJ Remme, JH Kingma, JA Kragten, R van Nieuwenhuizen & BA (Ben) van Hout (1996) - Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands - European Heart Journal, 17 (May), 731-740
- Fernando Albuquerque de Almeida, Maiwenn Al, R Koymans, J Riistame, S Pauws & Hans Severens (2020) - Impact of hospitalisation on health-related quality of life in patients with chronic heart failure - Health and Quality of Life Outcomes, 18 (1) - doi: 10.1186/s12955-020-01508-8
- Marscha Holleman, Maiwenn Al, Remziye Zaim, HJM Groen & Carin Groot (2019) - Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations - The European Journal Of Health Economics, 21, 153-164 - doi: 10.1007/s10198-019-01117-3
- RA Vremans, J Geenen, AM Hovels, WG Goettsch, HGM Leufkens & Maiwenn Al (2019) - Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. - Applied Health Economics and Health Policy, 17, 883-893 - doi: 10.1007/s40258-019-00496-1 - [link]
- Marscha Holleman, H van Tinteren, HJM Groen, Maiwenn Al & Carin Groot (2019) - First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis - OncoTargets and Therapy, 12, 1413-1421 - doi: 10.2147/ott.S189438
- E Alemao, S Johal, Maiwenn Al & Maureen Molken (2018) - Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. - Value in Health, 21 (2), 193-202 - doi: 10.1016/j.jval.2017.05.020
- E Alemao, Maiwenn Al, AA Boonen, MD Stevenson, SMM Verstappen, K Michaud, ME Weinblatt & Maureen Molken (2018) - Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. - PLoS One (print), 13 (10) - doi: 10.1371/journal.pone.0205013
- Nasuh Buyukkaramikli, Saskia Groot, R Riemsma, D Fayter, N Armstrong, P Portegijs, S Duffy, J Kleijnen & Maiwenn Al (2018) - Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-018-0708-4
- Margreet Franken, Isaac Corro Ramos, Jeanine Los & Maiwenn Al (2018) - The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios - BMC Family Practice, 19 (31) - doi: 10.1186/s12875-018-0714-9 - [link]
- Isaac Corro Ramos, GAK van Voorn, P (Pepijn) Vemer, TL Feenstra & Maiwenn Al (2017) - A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data - Value in Health, 20 (8), 1041-1047 - doi: 10.1016/j.jval.2017.04.016
- N Büyükkaramikli, Hedwig Blommestein, R Riemsma, N Armstrong, FJ Clay, J Ross, G Worthy, Hans Severens, J Kleijnen & Maiwenn Al (2017) - Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-017-0528-y
- NC Büyükkaramikli, Saskia Groot, D Fayter, R Wolff, N Armstrong, L Stirk, G Worthy, Fernando Albuquerque de Almeida, J Kleijnen & Maiwenn Al (2017) - Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-017-0581-6
- Isaac Corro Ramos, SK Lhachimi, A Gerber-Grote & Maiwenn Al (2016) - Cost Recommendation under Uncertainty in IQWiG’s Efficiency Frontier Framework - Medical Decision Making - doi: 10.1177/0272989X16636856
- R Riemsma, Isaac Corro Ramos, R Birnie, Nasuh Buyukkaramikli, N Armstrong, S Ryder, S Duffy, G Worthy, Maiwenn Al, Hans Severens & J Kleijnen (2016) - Integrated sensor-augmented pump therapy system [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation - Health Technology Assessment, 20 (17) - doi: 10.3310/hta20170
- P (Pepijn) Vemer, Isaac Corro Ramos, GAK van Voorn, Maiwenn Al & TL Feenstra (2016) - AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users - Pharmacoeconomics (Print), 34 (4), 349-361 - doi: 10.1007/s40273-015-0327-2
- J Bindels, B Ramaekers, Isaac Corro Ramos, L Mohseninejad, S Knies, J Grutters, M Postma, Maiwenn Al, TL Feenstra & M Joore (2016) - Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives - Pharmacoeconomics (Print), 34 (3), 315-322 - doi: 10.1007/s40273-015-0346-z
- Hedwig Blommestein, N Armstrong, S Ryder, S Deshpande, G Worthy, C Noake, R Riemsma, J Kleijnen, Hans Severens & Maiwenn Al (2016) - Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene - Pharmacoeconomics (Online), 34 (1), 23-31 - doi: 10.1007/s40273-015-0318-3
- LT (Laura) Burgers, Ken Redekop, Maiwenn Al, SK (Stefan) Lhachimi, N Armstrong, S Walker, C Rothery, M Westwood & Hans Severens (2016) - Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients - European Journal of Health Economics (HEPAC), 1-12 - doi: 10.1007/s10198-016-0824-z
- E Alemao, S Joo, H Kawabata, Maiwenn Al, PD Allison, Maureen Molken, ML Frits, CK Iannaccone, NA Schadik & ME Weinsblatt (2016) - Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data - Arthritis Care & Research, 68 (3), 308-317 - doi: 10.1002/acr.22678
- E Alemao, H Cawston, F Bourhis, Maiwenn Al, Maureen Molken, KP Liao & DH Solomon (2016) - Cardiovascular risk factor management in patients with RA compared to matched non-RA patients - Rheumatology, 55 (5), 809-816 - doi: 10.1093/rheumatology/kev427
- N Armstrong, LT (Laura) Burgers, S Deshpande, Maiwenn Al, R Riemsma, SR Vallabhaneni, P Holt, Hans Severens & J Kleijnen (2015) - The use of fenestrated and branched endovascular aneurysm repairfor juxtarental and thoracoabdominal aneurysms: a systematic review and cost-effectiveness analysis - Health Technology Assessment, 18 (70) - doi: 10.3310/hta18700
- Isaac Corro Ramos, Maureen Molken & Maiwenn Al (2015) - Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis - Value in Health, 18 (1), 100-109 - doi: 10.1016/j.jval.2014.09.003.
- Olena Mandrik, Isaac Corro Ramos, Saskia Knies, Maiwenn Al & Hans Severens (2015) - Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine - Cancer Management and Research (online), 2015 (7), 279-289 - doi: 10.2147/CMAR.S79258
- KM (Kim Marleine) Holtzer - Goor, JG (Jennifer G.) Gaultney, P van Houten, AS Wagg, Simone Huygens, MM Nielen, CP Albers-Heitner, Ken Redekop, Maureen Molken & Maiwenn Al (2015) - Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands. - PLoS One (print), 10 (10) - doi: 10.1371/journal.pone.0138225
- P Whiting, Maiwenn Al, LT (Laura) Burgers, M Westwood, S Ryder, Martine Lips, N Armstrong, A Allen, Hans Severens & J Kleijnen (2014) - Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. - Health Technology Assessment, 18 (8) - doi: 10.3310/hta18180
- Isaac Corro Ramos, Maureen Molken & Maiwenn Al (2013) - The role of value-of-information analysis in a health care research priority setting: a theoretical case study - Medical Decision Making, 33 (4), 472-489 - doi: 10.1177/0272989X12468616
- MRC Hendriks, Maiwenn Al, MHC Bleijlevens, JCM van Haastregt, HFJM Crebolder, JTM van Eijk & SMAA Evers (2013) - Continuous versus intermittent data collection of health care utilization - Medical Decision Making, 33, 998-1008 - doi: 10.1177/0272989X13482045
- P (Pepijn) Vemer, PFM (Paul) Krabbe, TL (Talitha) Feenstra, GAK van Voorn, Isaac Corro Ramos & Maiwenn Al (2013) - Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force - Value in Health, 16, 1106-1107 - doi: 10.1016/j.jval.2013.06.015
- Leona Roijen, TJEM Bakker, Maiwenn Al, J van der Lee, Hugo Duivenvoorden, MW Ribbe & Robbert Huijsman (2013) - Economic evaluation alongside a single RCT of an integrative psychotherapeutic nursing home programme - BMC Health Services Research, 13 (370), 1-13 - doi: 10.1186/1472-6963-13-370
- Martine Lips, Maiwenn Al, KM Beeh, D Bowles, JMG von der Schulenburg, J Lungershausen, BU Monz, H Schmidt, C Vogelmeier & Maureen Molken (2013) - Cost-effectiveness of triotropium versus salmeterol: the POET-COPD trial - European Respiratory Journal, 41 (3), 556-564 - doi: 10.1183/09031936.000.27212
- P (Pepijn) Vemer, Maiwenn Al, M (Mark) Oppe & Maureen Molken (2013) - A Choice That Matters? Simulation study on the impact of direct meta-analysis methods on health economic outcomes - Pharmacoeconomics (Print), 31 (8), 719-730 - doi: 10.1007/s40273-013-0067-0
- Menno Kiel, Esther Röder, Roy Gerth van Wijk, Maiwenn Al, WCJ Hop & Maureen Molken (2013) - Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy - Journal of Allergy and Clinical Immunology, 132, 353-360 - doi: 10.1016/j.jaci.2013.03.013
- Maiwenn Al (2012) - Cost-Effectiveness Acceptability Curves Revisited - Pharmacoeconomics (Print), 31 (2), 93-100 - doi: 10.1007/s40273-012-0011-8
- Martine Lips, Maiwenn Al, KM Beeh, D Bowles, JM Graf von der Schulenburg, J Lungershausen, BU Monz, H Schmidt, C Vogelmeier & Maureen Molken (2012) - Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial - European Respiratory Journal - doi: 10.1183/09031936.00027212
- E Alemao, S Rajagopalan, RE Curiel, J Purvis, SL Yang & Maiwenn Al (2011) - Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma - Journal of Medical Economics, 14 (2), 245-252 - doi: 10.3111/13696998.2011.566296
- EJI Hoogendoorn, Maureen Molken, RT Hoogenveen, Maiwenn Al & TL (Talitha) Feenstra (2011) - Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease - Value in Health, 14 (8), 1039-1047 - doi: 10.1016/j.jval.2011.06.008
- M (Mark) Oppe, Maiwenn Al & Maureen Molken (2011) - Comparing Methods of Data Synthesis - Pharmacoeconomics (Print), 29 (3), 239-250 - doi: 10.2165/11539870-000000000-00000
- Maiwenn Al, Leona Roijen, Siok Swan Tan & Jan Bakker (2010) - Cost-consequence analysis of remifentanil-based analgo-sedation vs. conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands - Critical Care, 14 (195), 1-10 - doi: 10.1186/cc9313
- Lucas Goossens, B Standaert, Nico Hartwig, AM Hovels & Maiwenn Al (2009) - Conclusions on cost-effectiveness of rotavirus vaccination highly dependent on assumptions - Vaccine, 27, 2531-2532 - doi: 10.1016/j.vaccine.2009.02.036
- Leona Roijen, P (Paul) Verboom, R Philips & Maiwenn Al (2009) - The cost utility of solifenacin in the threatment of overactive bladder - International Urology and Nephrology, 41, 293-298 - doi: 10.1007/s11255-008-9448-2
- CM (Carmen) Galani, Maiwenn Al, H Schneider & FFH Rutten (2008) - Uncertainty in decision-making: value of additional information in the cost-effectivenss of lifestyle intervention in overweight and obese people - Value in Health, 11 (3), 424-434 - doi: 10.1111/j.1524-4733.2007.00284.x
- B van den Berg, Maiwenn Al, Job Exel, Marc Koopmanschap & Werner Brouwer (2008) - Economic valuation of informal care: conjoint analysis applied in a heterogeneous population of informal caregivers - Value in Health, 11 (7), 1041-1050 - doi: 10.1111/j.1524-4733.2008.00357.x
- Lucas Goossens, B Standaert, Nico Hartwig, AM Hovels & Maiwenn Al (2008) - The cost-utility of rotavirus vaccination with Rotarix TM (RIX4414) in the Netherlands - Vaccine, 26, 1118-1127 - doi: 10.1016/j.vaccine.2007.11.070
- JB (Jan) Oostenbrink, Maiwenn Al, M (Mark) Oppe & Maureen Molken (2008) - Expected value of perfect information: An Empirical example of reducing decision uncertainty by conducting additional research - Value in Health, 11, 1070-1080 - doi: 10.1111/j.1524-4733.2008.00389.x
- CAM Bouwmans - Frijters, AME Lintsen, Maiwenn Al, CM Verhaak, Rene Eijkemans, Dik Habbema, DDM Braat & Leona Roijen (2008) - Absence from work and emotional stress in woman undergoing IVF or ICSI: An analysis of IVF-related absence from work in women and the contribution of general and emotional factors. - Acta Obstetricia et Gynecologica Scandinavica, 87, 1169-1175 - doi: 10.1080/00016340802460305
- LM (Leida) Lamers, R Stupp, Martin Bent, Maiwenn Al, T Gorlia, JB Wasserfallen, N Mittmann, SJ Seung, R Crott & CAUD Groot (2008) - Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme - A report from the EORTC 26981/22981 NCI-C CE3 intergroup study - Cancer, 112 (6), 1337-1344 - doi: 10.1002/cncr.23297
- Maiwenn Al, N Maniadakis, Els Grijseels & Mirjam Janssen (2008) - Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands - Value in Health, 11 (4), 589-599 - doi: 10.1111/j.1524-4733.2007.00303.x
- JM Lamers, R Stupp, Martin Bent, Maiwenn Al, T Gorlia, JB Wasserfallen, N Mittmann, SJ Seung, R Crott & Carin Groot (2008) - Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme - Cancer, 112 (6), 1337-1344
- Siok Swan Tan, Leona Roijen, Maiwenn Al, CAM Bouwmans - Frijters, ME Hoogendoorn, PE Spronk & Jan Bakker (2008) - A microcosting study of intensive care unit stay in the Netherlands - Journal of Intensive Care Medicine, 23 (4), 250-257 - doi: 10.1177/0885066608318661
- B (Bart) van der Berg, Maiwenn Al, W Brouwer, Job Exel & Marc Koopmanschap (2005) - Economic valuation of informal care: The conjoint measurement method applied to informal caregiving - Social Science & Medicine, 61 (6), 1342-1355 - doi: 10.1016/j.socscimed.2005.01.029
- JB (Jan) Oostenbrink & Maiwenn Al (2005) - The analysis of incomplete cost data due to dropout - Health Economics, 14 (8), 763-776 - doi: 10.1002/hec.966
- Maiwenn Al, TL (Talitha) Feenstra & BA (Ben) van Hout (2005) - Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty - Health Economics, 14 (7), 655-667 - doi: 10.1002/hec.973
- HJ Bernelot Moens, JJ Croonenborg, Maiwenn Al & PM Bemt (2004) - Richtlijn 'NSAID-gebruik en preventie van maagschade' - Nederlands Tijdschrift voor Geneeskunde, 148, 604-608
- P (Pedram) Sendi, Maiwenn Al & FFH Rutten (2004) - Portfolio theory and cost- effectiveness analysis: A further discussion - Value in Health, 7, 595-601 - doi: 10.1111/j.1524-4733.2004.75010.x
- JB (Jan) Oostenbrink, Maureen Molken, Maiwenn Al, JA Noord & W van Vincken (2004) - One-year cost-effectiveness of tiotropium to treat chronic obstructive pulmonary disease - European Respiratory Journal, 23, 241-249 - doi: 10.1183/09031936.03.00083703
- P (Pedram) Sendi, Maiwenn Al, A Gafni & S Birch (2004) - Portfolio theory and the alternative decision rule of cost- effectiveness analysis: theoretical and practical considerations - Social Science & Medicine, 58, 1853-1855 - doi: 10.1016/j.socscimed.2004.01.001
- P (Pedram) Sendi, Maiwenn Al & H Zimmermann (2004) - A risk-adjusted approach to comparing the return on the investment in health care programs - International Journal of Health Care Finance and Economics, 4, 199-210
- Maiwenn Al & Werner Brouwer (2004) - Decision makers views on health care objectives and budget constraints; results from a pilot - Health Policy, 70, 33-48 - doi: 10.1016/j.healthpol.2004.01.009
- P (Pedram) Sendi, Maiwenn Al & M Battegay (2004) - Optimising the performance of an outpatient setting - Swiss Medical Weekly, 134, 44-49
- P (Pedram) Sendi, Maiwenn Al, A Gafni & S Birch (2003) - Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources - Social Science & Medicine, 57, 2207-2215 - doi: 10.1016/S0277-9536(03)00086-8
- P (Pedram) Sendi & Maiwenn Al (2003) - Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty - Social Science & Medicine, 57, 969-974 - doi: 10.1016/S0277-9536(02)00477-X
- JB (Jan) Oostenbrink, Maiwenn Al & Maureen Molken (2003) - Methods to analyse cost data of patients who withdraw in a clinical trial setting - Pharmacoeconomics (Print), 21, 1103-1112 - doi: 10.2165/00019053-200321150-00004
- H (Harry) Suryapranata, JP (Jan Paul) Ottervanger, E Nibbering, AWJ Hof, JCA Hoorntje, Maarten Boer, Maiwenn Al & F Zijlstra (2001) - Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction - Heart, 85 (6), 667-671
- C Chevat, BM Pena, Maiwenn Al & FFH Rutten (2001) - Health care resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective - Pharmacoeconomics (Print), 19 (1), 17-32
- Maiwenn Al & BA (Ben) van Hout (2000) - A bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty - Health Economics, 9, 599-609
- Maiwenn Al, BA (Ben) van Hout, CM Bowine & FFH Rutten (1998) - Sample size calculation in economic evaluations - Health Economics, 7, 327-335
- Maiwenn Al, Marc Koopmanschap, PJ van Enckevort, A Geertsma, W van der Bij, WJ Boer & EM ten Vergert (1998) - Coast- effectiveness of lung transplantation in the Netherlands - Chest, 113 (1), 124-130
- NF de Keizer, Gouke Bonsel, Maiwenn Al & RJBJ Gemke (1998) - The relation between TISS and real paedeatric ICU costs: a case study with generalizable methodology - Intensive Care Medicine, 24, 1062-1069 - doi: 10.1007/s001340050717
- PJ van Enckevort, EM TenVergert, Gouke Bonsel, A Geertsma, W van der Bij, WJ Boer, Marc Koopmanschap, Maiwenn Al & FFH Rutten (1998) - Technology Assessment of the Dutch lung transplantation program - International Journal of Technology Assessment in Health Care, 14 (2), 344-356
- Maiwenn Al, BC (Bowine) Michel & FFH Rutten (1996) - The Cost Effectiveness of Diclofenac Plus Misoprostol Compared with Diclofenac Monotherapy in Patients with Rheumatoid Arthritis - Pharmacoeconomics (Print), 10 (2), 141-151
- BC (Bowine) Michel, Maiwenn Al, WJ Remme, JH Kingma, JA Kragten, R van Nieuwenhuizen & BA (Ben) van Hout (1996) - Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands - European Heart Journal, 17 (May), 731-740
- N Armstrong, Nasuh Buyukkaramikli, Hannah Penton, R Riemsma, Pim Wetzelaer, V Huertas Carrera, SL Swift, T Drachen, H Raatz, S Ryder, D Shah, T Buksnys, G Worthy, S Duffy, Maiwenn Al & J Kleijnen (2020) - Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis - Health Technology Assessment, 51, 1-220 - doi: 10.3310/hta24510.
- Maiwenn Al & Werner Brouwer (2004) - Stimuleren doelmatig gebruik van zuurpompremmers in de onderhoudsbehandeling - TSG, 82, 191-195
- Ivonne Buijt, Maiwenn Al & FFH Rutten (2003) - Protonpompremmers, kostenremmers? - Pharmaceutisch Weekblad, 138, 1194-1199
- Ivonne Buijt, Maiwenn Al & FFH Rutten (2003) - Protonpompremmers, kostenremmers? . - Pharmaceutisch Weekblad, 138, 1428-1429
- JRBJ Brouwers, EN van Roon, M Postma & Maiwenn Al (2000) - Kosteneffectiviteit van NSAID's - Altijd gastoprotectie? - Pharmaceutisch Weekblad, 135 (5), 172-175
- HJ (Herman) Stoevelaar & Maiwenn Al (1995) - Medische statistiek; over getallen die leven en worden geleefd - Klinische Fysica, 1 (1), 25-29
- N Armstrong, Nasuh Buyukkaramikli, Hannah Penton, R Riemsma, Pim Wetzelaer, V Huertas Carrera, SL Swift, T Drachen, H Raatz, S Ryder, D Shah, T Buksnys, G Worthy, S Duffy, Maiwenn Al & J Kleijnen (2020) - Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis - Health Technology Assessment, 51, 1-220 - doi: 10.3310/hta24510.
- Maiwenn Al & Werner Brouwer (2004) - Stimuleren doelmatig gebruik van zuurpompremmers in de onderhoudsbehandeling - TSG, 82, 191-195
- Ivonne Buijt, Maiwenn Al & FFH Rutten (2003) - Protonpompremmers, kostenremmers? - Pharmaceutisch Weekblad, 138, 1194-1199
- Ivonne Buijt, Maiwenn Al & FFH Rutten (2003) - Protonpompremmers, kostenremmers? . - Pharmaceutisch Weekblad, 138, 1428-1429
- JRBJ Brouwers, EN van Roon, M Postma & Maiwenn Al (2000) - Kosteneffectiviteit van NSAID's - Altijd gastoprotectie? - Pharmaceutisch Weekblad, 135 (5), 172-175
- HJ (Herman) Stoevelaar & Maiwenn Al (1995) - Medische statistiek; over getallen die leven en worden geleefd - Klinische Fysica, 1 (1), 25-29
- Maiwenn Al (2000) - Modelleren en omgaan met onzekerheid - Elsevier gezondheidszorg
- Maiwenn Al (2000) - Modelleren en omgaan met onzekerheid - Elsevier gezondheidszorg
- Maiwenn Al (2001) - Certain methods for uncertain situations. Evaluating health care technologies - EUR
- Maiwenn Al (2001) - Certain methods for uncertain situations. Evaluating health care technologies - EUR
- Penny Whiting, Maiwenn Al, M Westwood, Isaac Corro Ramos, S Ryder, N Armstrong, K Misso, J Ross, Hans Severens & J Kleijnen (2016) - Viscoelastic point-of-care testing to assist with the diagnosis management and monitoring of haemostasis a systematic review and cost-effectiveness analysis - doi: 10.3310/hta19580 - Health Technology Assessment
- R Riemsma, Maiwenn Al, Isaac Corro Ramos, SN Deshpande, N Armstrong, YC Lee, SD Ryder, C Noake, Marieke Krol, M (Mark) Oppe, J Kleijnen & Hans Severens (2013) - SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis - doi: 10.3310/hta17610 - National Institute for Health Research
- Maiwenn Al (1995) - Hulpambulances nader beschouwd - Begeleidingscommissie experiment hulpambulancevervoer
- M Westwood, Maiwenn Al, LT (Laura) Burgers, Ken Redekop, SK (Stefan) Lhachimi, N Armstrong, H Raatz, K Misso, Hans Severens & J Kleijnen (2013) - A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD. - doi: 10.3310/hta17090 - Health Technology Assessment
- Martine Lips, Maureen Molken, R Hoogeveen, Maiwenn Al & TL (Talitha) Feenstra (2010) - Comparing the cost-effectiveness of a wide range of COPD interventions using a stochastic, dynamic, population model for COPD - Instituut Beleid & Management Gezondheidszorg
- Penny Whiting, Maiwenn Al, M Westwood, Isaac Corro Ramos, S Ryder, N Armstrong, K Misso, J Ross, Hans Severens & J Kleijnen (2016) - Viscoelastic point-of-care testing to assist with the diagnosis management and monitoring of haemostasis a systematic review and cost-effectiveness analysis - doi: 10.3310/hta19580 - Health Technology Assessment
- R Riemsma, Maiwenn Al, Isaac Corro Ramos, SN Deshpande, N Armstrong, YC Lee, SD Ryder, C Noake, Marieke Krol, M (Mark) Oppe, J Kleijnen & Hans Severens (2013) - SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis - doi: 10.3310/hta17610 - National Institute for Health Research
- Maiwenn Al (1995) - Hulpambulances nader beschouwd - Begeleidingscommissie experiment hulpambulancevervoer
- Penny Whiting, Maiwenn Al, M Westwood, Isaac Corro Ramos, S Ryder, N Armstrong, K Misso, J Ross, Hans Severens & J Kleijnen (2016) - Viscoelastic point-of-care testing to assist with the diagnosis management and monitoring of haemostasis a systematic review and cost-effectiveness analysis - doi: 10.3310/hta19580 - Health Technology Assessment
- R Riemsma, Maiwenn Al, Isaac Corro Ramos, SN Deshpande, N Armstrong, YC Lee, SD Ryder, C Noake, Marieke Krol, M (Mark) Oppe, J Kleijnen & Hans Severens (2013) - SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis - doi: 10.3310/hta17610 - National Institute for Health Research
- Maiwenn Al (1995) - Hulpambulances nader beschouwd - Begeleidingscommissie experiment hulpambulancevervoer
- M Westwood, Maiwenn Al, LT (Laura) Burgers, Ken Redekop, SK (Stefan) Lhachimi, N Armstrong, H Raatz, K Misso, Hans Severens & J Kleijnen (2013) - A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD. - doi: 10.3310/hta17090 - Health Technology Assessment
- Martine Lips, Maureen Molken, R Hoogeveen, Maiwenn Al & TL (Talitha) Feenstra (2010) - Comparing the cost-effectiveness of a wide range of COPD interventions using a stochastic, dynamic, population model for COPD - Instituut Beleid & Management Gezondheidszorg
- M Westwood, Maiwenn Al, LT (Laura) Burgers, Ken Redekop, SK (Stefan) Lhachimi, N Armstrong, H Raatz, K Misso, Hans Severens & J Kleijnen (2013) - A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD. - doi: 10.3310/hta17090 - Health Technology Assessment
- Martine Lips, Maureen Molken, R Hoogeveen, Maiwenn Al & TL (Talitha) Feenstra (2010) - Comparing the cost-effectiveness of a wide range of COPD interventions using a stochastic, dynamic, population model for COPD - Instituut Beleid & Management Gezondheidszorg
Advanced Health Economic Modelling EuHEM
- Level
- master
- Year
- 2021
- Year Level
- master
- Course Code
- GW4587M
Advanced Research Methods
- Year
- 2021
- Year Level
- master, master
- Course Code
- GW4588M
Advanced Research Methods
- Level
- master - jaar 2
- Year
- 2021
- Year Level
- master - jaar 2
- Course Code
- GW4003MD
Advanced Health Economic Modelling
- Year
- 2021
- Year Level
- master, master, master
- Course Code
- GW4563M
Advanced Research Methods
- Level
- master
- Year
- 2021
- Year Level
- master
- Course Code
- GW4003MV
Master HEPL-HE 2021-2022
- Year
- 2021
- Course Code
- GWMTTHEPL
Advanced Health Economic Modelling EuHEM
- Level
- master
- Year
- 2021
- Year Level
- master
- Course Code
- GW4587M
Advanced Research Methods
- Year
- 2021
- Year Level
- master, master
- Course Code
- GW4588M
Advanced Research Methods
- Level
- master - jaar 2
- Year
- 2021
- Year Level
- master - jaar 2
- Course Code
- GW4003MD
Advanced Health Economic Modelling
- Year
- 2021
- Year Level
- master, master, master
- Course Code
- GW4563M
Advanced Research Methods
- Level
- master
- Year
- 2021
- Year Level
- master
- Course Code
- GW4003MV
Master HEPL-HE 2021-2022
- Year
- 2021
- Course Code
- GWMTTHEPL